Skip to main content
ANAPTYSBIO, INC logo

ANAPTYSBIO, INC — Investor Relations & Filings

Ticker · ANAB ISIN · US0327241065 LEI · 529900HH4WQT03IG1A12 US Professional, scientific and technical activities
Open in API
Filings indexed 636 across all filing types
Latest filing 2018-08-08 Director's Dealing
Country US United States of America
Listing US ANAB

About ANAPTYSBIO, INC

https://www.anaptysbio.com/

AnaptysBio, Inc. is a clinical-stage biotechnology company that focuses on the discovery and development of innovative immunology therapeutics. The company specializes in advancing immune cell-modulating antibodies designed to treat autoimmune and inflammatory diseases. Its therapeutic candidates target key pathways in the immune system to address significant unmet medical needs for various patient populations.

Recent filings

Filing Released Lang Actions
FORM 3 SUBMISSION
Director's Dealing
2018-08-08 English
10-Q
Interim / Quarterly Report Q2 2018
2018-08-07 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 7, 2018, by AnaptysBio, Inc. It announces the issuance of a press release regarding financial results for the six months ended June 30, 2018. The document explicitly states that the press release is attached as Exhibit 99.01 and that the information is not filed for purposes of certain securities laws, indicating this is an announcement of financial results rather than the full financial report itself. The document length is 3815 characters, which is relatively short and consistent with an announcement rather than a full report. The key section is Item 2.02 "Results of Operations and Financial Condition," which typically corresponds to an Earnings Release. Therefore, this document is best classified as an Earnings Release (ER).
2018-08-07 English
FORM 4 SUBMISSION
Director's Dealing
2018-07-11 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated June 12, 2018, reporting the submission of matters to a vote of security holders at the company's 2018 Annual Meeting of Stockholders. It details the election results of directors and ratification of the independent auditor. The content focuses on voting results from the annual meeting, not the full annual report or financial statements. The document length is 3463 characters, which is relatively short and consistent with a voting results announcement. Therefore, this filing fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2018-06-12 English
FORM 4 SUBMISSION
Director's Dealing
2018-06-11 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.